Holen Sie sich die Stockscreener-App
35.80
2.76%
0.96
Schlusskurs vom Vortag:
$34.84
Offen:
$34.84
24-Stunden-Volumen:
240.15K
Relative Volume:
0.61
Marktkapitalisierung:
$1.92B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+2.29%
1M Leistung:
+37.53%
6M Leistung:
+227.24%
1J Leistung:
+242.91%
1-Tages-Spanne:
$33.89
$36.50
1-Wochen-Bereich:
$33.80
$38.50
52-Wochen-Spanne:
$5.83
$38.50
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Firmenname
Zenas Biopharma Inc
Sektor
Branche
Telefon
857-271-2954
Adresse
852 WINTER STREET, SUITE 250, WALTHAM
Vergleichen Sie ZBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
35.80 | 1.87B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-20 | Eingeleitet | Wedbush | Outperform |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-05 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-08 | Eingeleitet | Citigroup | Buy |
| 2024-10-08 | Eingeleitet | Guggenheim | Buy |
| 2024-10-08 | Eingeleitet | Jefferies | Buy |
| 2024-10-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Zenas Biopharma Inc Aktie (ZBIO) Neueste Nachrichten
Zenas BioPharma : Corporate Presentation - MarketScreener
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO) - PR Newswire
Will Zenas BioPharma Inc. benefit from macro trendsEarnings Beat & Verified High Yield Trade Plans - newser.com
Is Zenas BioPharma Inc. stock a dividend growth opportunityDollar Strength & High Conviction Investment Ideas - newser.com
Will Zenas BioPharma Inc. stock keep outperforming rivalsMarket Sentiment Summary & Verified Technical Trade Signals - newser.com
Will Zenas BioPharma Inc. stock remain a Wall Street favoriteEarnings Performance Report & Risk Controlled Swing Alerts - newser.com
What analysts say about Zenas BioPharma Inc stockMomentum Trading Signals & Low Cost Market Strategies - earlytimes.in
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
What dividend safety score for Zenas BioPharma Inc. stockTrade Exit Summary & Long Hold Capital Preservation Tips - newser.com
Price momentum metrics for Zenas BioPharma Inc. explainedBuy Signal & Fast Moving Stock Watchlists - newser.com
From Olema To Insmed: Are These High-Flying Biotechs Still Worth Buying? - RTTNews
Strategies to average down on Zenas BioPharma Inc.2025 Market Sentiment & Stepwise Entry/Exit Trade Alerts - newser.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Connect - ACCESS Newswire
2025-11-18 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Connect | NDAQ:ZBIO | Press Release - Stockhouse
Zenas Biopharma stock hits all-time high at 36.7 USD By Investing.com - Investing.com Nigeria
Zenas BioPharma (ZBIO) Price Target Increased by 10.51% to 44.44 - Nasdaq
Will Zenas BioPharma Inc. stock sustain high P E ratiosMarket Sentiment Report & Daily Stock Trend Reports - newser.com
2025-11-16 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Reach Out | NDAQ:ZBIO | Press Release - Stockhouse
How risky is Zenas BioPharma Inc. stock nowBull Run & Real-Time Chart Breakout Alerts - newser.com
Is Zenas BioPharma Inc. stock ready for breakoutEarnings Growth Report & Expert Verified Movement Alerts - newser.com
Published on: 2025-11-15 02:01:43 - newser.com
Zenas BioPharma Reports Q3 2025 Financial Results - TipRanks
How to track smart money flows in Zenas BioPharma Inc.Trade Risk Report & Safe Entry Trade Signal Reports - newser.com
How Zenas BioPharma Inc. stock reacts to inflationary pressuresGap Down & Free Long-Term Investment Growth Plans - newser.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Zenas BioPharma price target raised to $37 from $34 at Morgan Stanley - TipRanks
Zenas BioPharma, Inc.: Promising Outlook with Positive Clinical Results and Strong Financial Position Supporting Buy Rating - TipRanks
Decoding Zenas BioPharma Inc (ZBIO): A Strategic SWOT Insight - GuruFocus
Zenas BioPharma, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2025 - MarketScreener
Zenas BioPharma Q3 Net Loss Narrows - MarketScreener
Earnings Flash (ZBIO) Zenas BioPharma Posts Q3 Net Loss $1.22 a Share, vs. FactSet Est of $0.83 Loss - MarketScreener
Zenas BioPharma, Inc. SEC 10-Q Report - TradingView
Finanzdaten der Zenas Biopharma Inc-Aktie (ZBIO)
Es liegen keine Finanzdaten für Zenas Biopharma Inc (ZBIO) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Zenas Biopharma Inc-Aktie (ZBIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
Oct 09 '25 |
Buy |
19.00 |
126,315 |
2,399,985 |
1,917,895 |
| ENRIGHT PATRICK G | Director |
Oct 09 '25 |
Buy |
19.00 |
105,265 |
2,000,035 |
1,832,669 |
| ENRIGHT PATRICK G | Director |
Oct 09 '25 |
Buy |
20.85 |
11,990 |
249,992 |
11,990 |
| MOULDER LEON O JR | See Remarks |
Oct 07 '25 |
Buy |
20.85 |
36,928 |
769,949 |
36,928 |
| Fairmount Funds Management LLC | Director |
Oct 07 '25 |
Buy |
19.00 |
316,219 |
6,008,161 |
2,209,025 |
| Lu Hongbo | Director |
Oct 07 '25 |
Buy |
19.00 |
263,160 |
5,000,040 |
321,983 |
| MOULDER LEON O JR | Chief Executive Officer |
Feb 18 '25 |
Buy |
6.67 |
25,000 |
166,750 |
266,155 |
| Xiao Ting | Director |
Feb 07 '25 |
Buy |
7.76 |
10,000 |
77,600 |
47,000 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 04 '24 |
Buy |
9.98 |
45,000 |
449,100 |
241,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 03 '24 |
Buy |
10.76 |
25,000 |
269,000 |
196,155 |
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):